Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV MOA mRNA vaccine mRNA vaccine Adenovirus vector vaccine Protein-based vaccine Adenovirus vector vaccine Adenovirus vector vaccine mRNA vaccine Inactivated virus Dosing 2 doses, 21 days apart 2 doses, 28 days apart 1 dose 2 doses, one month apart 2 doses, three months apart Sputnik Light requires one dose. 2 doses, four weeks apart 2 doses, three weeks apart Schedule The vaccine has been In a press release, the Gamaleya National D shown to be 89.3% effective Center of Epidemiology and Microbiology in in large-scale UK trials. Moscow claimed a large-scale Russian e 72% in the U.S. and 66% globally 76% in a U.S. study against Significantly, it is the first study saw 92% efficacy for its vaccine. t against moderate-to-severe symptomatic COVID-19; 100% 95% at least 7 days after 94.1% at least 14 days jab shown to be effective However, other scientists have voiced Efficacy results are presumed to 78% according to the World Health Efficacy disease; 85% effective against effective severe disease; 85% a dose 2 after dose 2 against the new UK variant concerns this claim is based on too few be released in May 2021. Organization severe disease, 28 days after a efficacy against symptomatic of COVID-19 in such a trial. cases. Although the vaccine was trialled on i single dose. COVID-19 in those 65+ 96% against original 18,000 people, the efficacy claim has been l coronavirus, 86% against B. based on an analysis of only 39 individuals s 1.1.7, 49% against B.1.351. to test positive with coronavirus. Frozen; can be stored Ultra-cold freezer Stable at regular fridge refrigerated for up to Stable in refrigerator for at Sputnik Light is refrigerator stable at 36.5 - Storage required, for up to 6 temperature for up to 3 months Regular fridge temperature Stable in refrigerator for 3 months Refrigerator stable at 36.5 - 46.4ºF. 30 days prior to first least 6 months 46.4ºF. months and stable for 2 years at -4ºF. use. U.K. EUA Dec 2, 2020 Jan 8, 2021 delayed, but in prog In progress Dec 30, 2020 A Phase 3 trial in progress, U.S. EUA Dec 11, 2020 Dec 18, 2020 Feb 27, 2021 delayed, but in prog u EUA expected in May 2021 t E.U. EUA Dec 21, 2020 Jan 6, 2021 Mar 11, 2021 *exploratory talks Jan 29, 2021 h Russia Nov 2020 o Canada Dec 23, 2020 r W.H.O. May 7, 2021 i March 2021: PAUSED - Some EU countries decided to restrict z the use of AstraZeneca's a 4/13/2021: PAUSED out of vaccine to older citizens after t "abundance of caution" due to cases of blood clots were blood clot and low platelet reports assessed in younger people. i Countries include France, o Germany, and Denmark, n amongst others. 4/23/2021: pause lifted March/April 2021: pause lifted A Authorized for ages 18+, with Authorized for ages Authorized for ages 12+ Authorized for ages 18+ age limitations in EU certain Approved for ages 18+ g 18+ e countries 3/16/2020: Moderna Q1 begins Phase 1 human clinical trial for their 2020 mRNA COVID-19 vaccine in the U.S. Q2 4/29/2020: Human trials 4/29/2020: Researchers begin Phase 2020 begin in Germany. 1 trial. 5/12/2020: Moderna receives Fast Track designation from the FDA to proceed with a Phase 2 study of their vaccine. 5/1/2020: Novavax 5/18/2020: Moderna announces a combined releases interim data Phase 1/2 clinical trial, with May 2020: CureVac announces 5/5/2020: Pfizer and from their Phase 1 phase 1 starting in Austraia positive results for vaccine BioNtech Dose 1st U.S. clinical trial, stating and Phase 2 to be candidate in preclinical Participants. plans for a Phase 3 conducted in multiple expieriments. trial to begin in July. countries following the 5/29/2020: Moderna results of Phase 1. announces purpose and enrollment of Phase 2 clinical trial. Enrollment was completed July 8. D e v e l o p m e n t H i g h l i g h t s Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV 6/6/2020: Researchers confirm June 2020: The Gamaleya Research promising results from trial in Institute begins clinical trials for a monkeys, stating the vaccine is combination adenovirus vaccine. genetically stable and seems to be safe in animals. 7/14/2020: Moderna publishes interim results of their Phase 1 7/20/2020: AstraZeneca's trial in The New 7/30/2020: Single dose of J&J Phase 1 human clinical trial 7/18/20: Phase 3 trial begins in the Q3 England Journal of vaccine candidate demonstrates results are published in The UAE, with subsequent Phase 3 trials Medicine. robust protection in pre-clinical Lancet; results show vaccine 2020 in Peru and Morocco. 7/27/2020: Moderna studies. is safe and create an immune begins Phase 3 clinical response. trial, enrolling 30,000 adults across the U.S. 8/4/2020: Novavax announces the results of Phase 1 of the Phase 1/2 clinical trial stating the vaccine was "generally well- 8/12/2020: Peer- tolerated and elicited robust Reviewed Phase 1/2 antibody responses." Data Published in Nature 8/24/2020: Novavax Magazine. announces the initation of Phase 2 of its Phase 1/2 clinical trials. Participants are enrolled in both the U.S. and Australia. 9/3/2020: Vaccine prevents severe clinical disease in pre- clinical studies. 9/23/2020: D Global Phase 3 'Ensemble' e Clinical Trials Begin 9/2/2020: Novavax v 9/25/2020: Interim results from announces publication of Phase 1/2a clinical trial support Phase 1 results in The New e further clinical development of England Journal of 9/4/2020: The Gamaleya Research Institute vaccine, but Phase 3 PAUSED Medicine. publishes the results of their Phase 1/2 l 9/1/2020: Phase 3 clinical trials after a serious medical event 9/24/2020: Novavax clinical trial, announcing their Sputnik V o begin in the U.S. experienced by 1 study announces initiation of vaccine yielded antibodies with only mild p participant. Phase 3 clincial trial using side effects. m 9/25/2020: Interim results from 10,000 participants across Phase 1/2a clinical trial support the U.K. (enrollment is e further clinical development of completed 11/30/2020). n vaccine, but Phase 3 PAUSED after a serious medical event t experienced by 1 study participant. H 10/17/2020: Research published in i The Lancet shares the results of a Q4 10/23/2020: Phase 3 Ensemble 10/17/2020: Phase 2/3 trial launches in Phase 1/2 trial, showing the vaccine g 2020 Trial resumes. India. stimulates the production of antibodies h and does not cause serious adverse l effects. 11/23/2020: AstraZeneca and 11/16/2020: Moderna i the University of Oxford 11/18/20: Pfizer and releases preliminary announce the initial results of 11/11/2020: The Russian Direct Investment g BioNTech conclude data from Phase 3 11/16/2020: Announcement of the Phase 3 clinical trials in the Fund announces that Sputnik's Phase 3 November 2020: CureVac reports h Phase 3 Study, meeting clinical trial, stating second Phase 3 clinical trial to U.K., Brazil, and South Africa. clinical trial demonstrated high efficacy positive interim Phase 1 data for all primary and their vaccine is 94.5% observe the use of two doses t The study showed the vaccine rates, determining a 92% efficacy rate for its COVID-19 vaccine candidate. secondary efficacy effective. The data is versus one. was safe and effective. Data the Sputnik V vaccine. s endpoints. released in full on from the study was published November 30. 11/19 in The Lancet. 12/2/2020: Moderna files to test their vaccine in adolescents 12/10/20: Pfizer and 12-18 years of age. December 2020: The Gamaleya Reserch 12/23/2020: CureVac begins BioNTech Announce Moderna announces 12/28/2020: Novavax Institute and AstraZeneca decide to Phase 3 trial using 36,500 Publication of Results the clinical trial on announces initiation of combine vaccines in an effort to increase participants across Europe and 12/30/2020: Sinopharm states their from Phase 3 Trial in March 10, 2021. Phase 3 efficacy trial in U.S. the efficacy of the AstraZeneca vaccine, Latin America. Results are vaccine has an efficacy rate of 79%. The New England 12/31/2020: Moderna and Mexico. with clinical trials beginning in February presumed to be released in May Journal of Medicine. publishes results of 2021. 2021. Phase 3 trial in The New England Journal of Medicine. D e v e l o p m e n t H i g h l i g h t s Pfizer-BioNTech Moderna Johnson & Johnson Novavax Oxford-AstraZeneca Sputnik V CureVac Sinopharm's BBIBP-CorV 1/13/2021: Interim Phase 1/2a Data published in New England Journal of Medicine 1/29/2021: Johnson & Johnson 1/13/2021: Interim Phase Q1 announce that their Phase 3 trial 1/2a Data published in New 2021 show their vaccine to be safe and England Journal of effective; the results of the trial Medicine. are published in The New England Journal of Medicine April 29, 2021. 2/25/21: Pfizer and 2/3/2021: Oxford and 2/12/2021: The European Union BioNTech Initiate a Study 2/4/2020: Novavax applies AstraZeneca publish more data 2/2/2021: The Gamaleya Research begins a "rolling review" process as Part of Broad 2/21/2021: Johnson & Johnson for emergency use from clinical trials regarding Institute, in part with Russia’s Ministry of of the Phase 3 trial, in order to Development Plan to announce upcoming clinical trial authorization with FDA, efficacy and prevention.